Literature DB >> 30306084

Rare forms of von Willebrand disease.

Emmanuel J Favaloro1,2.   

Abstract

von Willebrand disease (VWD) arises from deficiency and/or defect(s) of plasma von Willebrand factor (VWF). In turn, plasma VWF is an adhesive protein which primarily functions by anchoring platelets to regions of vascular injury, thereby assisting prevention of bleeding. There is a proportional reduction also in Factor VIII, due to the absence of the stabilizing and anti-proteolytic effect that VWF normally exerts. VWD is reportedly the most common inherited bleeding disorder and can be classified into quantitative and qualitative defects, with type 1 and 3 VWD respectively identifying partial and total quantitative deficiency of VWF, and type 2 VWD identifying qualitative defects of VWF. The relative incidence of each subtype of VWD differs according to the locality and the ability of clinicians and laboratories to correctly diagnose and classify cases. In general, type 1 VWD is considered the most common type of VWD, whereas types 2 and 3 represent rarer forms. However, in developing countries, and partly because of consanguinity, type 3 VWD is over-represented. This review primarily focuses on the rarer forms of VWD, which typically comprise types 2 (A, B, M and N) and 3 VWD. The review also mentions type 1 VWD, largely for completeness and comparability, and since purportedly "severe" type 1 VWD, albeit not a formally recognized subtype of type 1 VWD, would represent a relatively "rare" form of VWD.

Entities:  

Keywords:  diagnosis; management; rare forms; von Willebrand Disease (vWD)

Year:  2018        PMID: 30306084      PMCID: PMC6174185          DOI: 10.21037/atm.2018.09.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  39 in total

Review 1.  Biological therapies for von Willebrand disease.

Authors:  Emmanuel J Favaloro; Massimo Franchini; Giuseppe Lippi
Journal:  Expert Opin Biol Ther       Date:  2012-03-20       Impact factor: 4.388

2.  Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).

Authors:  Soma Mohammed; Emmanuel J Favaloro
Journal:  Methods Mol Biol       Date:  2017

3.  Laboratory Testing for von Willebrand Disease: The Past, Present, and Future State of Play for von Willebrand Factor Assays that Measure Platelet Binding Activity, with or without Ristocetin.

Authors:  Sarah Just
Journal:  Semin Thromb Hemost       Date:  2016-12-15       Impact factor: 4.180

Review 4.  Preanalytical issues that may cause misdiagnosis in haemophilia and von Willebrand disease.

Authors:  E J Favaloro; G Lippi
Journal:  Haemophilia       Date:  2017-12-22       Impact factor: 4.287

Review 5.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

6.  Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year 'real-world' experience.

Authors:  L Ardillon; C Ternisien; M Fouassier; M Sigaud; A Lefrançois; M Pacault; O Ribeyrol; E Fressinaud; P Boisseau; M Trossaërt
Journal:  Haemophilia       Date:  2015-03-10       Impact factor: 4.287

Review 7.  ABO blood group and von Willebrand factor: biological implications.

Authors:  Massimo Franchini; Silvia Crestani; Francesco Frattini; Cinzia Sissa; Carlo Bonfanti
Journal:  Clin Chem Lab Med       Date:  2014-09       Impact factor: 3.694

8.  von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).

Authors:  W L Nichols; M B Hultin; A H James; M J Manco-Johnson; R R Montgomery; T L Ortel; M E Rick; J E Sadler; M Weinstein; B P Yawn
Journal:  Haemophilia       Date:  2008-03       Impact factor: 4.287

9.  Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal.

Authors:  E J Favaloro
Journal:  J Thromb Haemost       Date:  2008-07-19       Impact factor: 5.824

Review 10.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.